Short-course radiotherapy in stage IV rectal cancer with resectable disease.
Adenocarcinoma
/ radiotherapy
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Male
Middle Aged
Pelvic Neoplasms
/ radiotherapy
Preoperative Care
Prognosis
Prospective Studies
Radiotherapy
/ methods
Rectal Neoplasms
/ pathology
Survival Rate
Rectal cancer
Resectable metastases
Short-course preoperative radiotherapy
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
17
02
2021
accepted:
17
05
2021
pubmed:
4
6
2021
medline:
8
2
2022
entrez:
3
6
2021
Statut:
ppublish
Résumé
Stage IV rectal cancer with resectable disease presents challenging issues, as the radical treatment of the whole disease is difficult. Surgery and chemotherapy (CT) play an unquestionable role, but the contribution of pelvic radiotherapy (RT) is not very clear. In 2009, we established a prospective treatment protocol that included CT, short-course preoperative radiotherapy (SCRT) with surgery of the primary tumour and all metastatic locations. Forty patients were included. Eight (20%) patients did not receive CT due to significant comorbidities. Radical surgery treatment was possible in 22 (55%) patients. The mean follow-up was 42.81 months (3.63-105.97). Overall survival at 24 and 36 months was 71.4% and 58.2%, respectively. There was good local control of the disease, as 97.2% of pelvic surgeries were R0 and there were no local recurrences. In stage IV with resectable metastatic disease, the proposed therapeutic regimen seems very appropriate in well selected patients able to tolerate the treatment. We bet on the role of pelvic RT, due to the good local control of the disease in our series.
Identifiants
pubmed: 34081292
doi: 10.1007/s12094-021-02647-0
pii: 10.1007/s12094-021-02647-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2482-2488Informations de copyright
© 2021. Federación de Sociedades Españolas de Oncología (FESEO).
Références
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.
doi: 10.1002/bjs.5506
Van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12 year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.
doi: 10.1016/S1470-2045(11)70097-3
Folkesson J, Birgisson H, Pahlman L, et al. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644–50.
doi: 10.1200/JCO.2005.08.144
Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20.
doi: 10.1016/S0140-6736(09)60484-0
Veenhof AA, Kropman RH, Engel AF, et al. Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery. Int J Colorectal Dis. 2007;22(5):507–13.
doi: 10.1007/s00384-006-0195-5
Radu C, Berglund A, Påhlman L, et al. Short-course preoperative radiotherapy with delayed surgery in rectal cancer—a retrospective study. Radiother Oncol. 2008;87(3):343–9.
doi: 10.1016/j.radonc.2007.11.025
Hatfield P, Hingorani M, Radhakrishna G, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009;92(2):210–4.
doi: 10.1016/j.radonc.2009.04.007
Pach R, Kulig J, Richter P, et al. Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer—treatment results at 5 year follow-up. Langenbecks Arch Surg. 2012;397:801–7.
doi: 10.1007/s00423-011-0890-8
Erlansson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal càncer (Stockholm III): a multicentre, randomized, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336–46.
doi: 10.1016/S1470-2045(17)30086-4
Cambray M, Gonzalez-Viguera J, Berenguer MA, et al. Short-course radiotherapy in locally advanced rectal cancer. Clin Transl Gastroenterol. 2020;11(6):e00162.
doi: 10.14309/ctg.0000000000000162
Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer. 1994;73(11):2680–6.
doi: 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol. 2013;24(7):1762–9.
doi: 10.1093/annonc/mdt124
Bisschop C, van Dijk TH, Beukema JC, et al. Short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical treatment in primary stage IV rectal cancer: long-term results of a phase II study. Ann Surg Oncol. 2017;24(9):2632–8.
doi: 10.1245/s10434-017-5897-0
Holliday EB, Hunt A, You YN, et al. Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017;8(6):990–7.
doi: 10.21037/jgo.2017.09.02
Yoon HI, Koom WS, Kim TH, et al. Upfront systemic chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases outcomes, compliance, and favorable prognostic factors. PLoS ONE. 2016;11(8):e0161475.
doi: 10.1371/journal.pone.0161475
Kim KH, Shin SJ, Cho MS, et al. A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. Radiother Oncol. 2016;118(2):369–74.
doi: 10.1016/j.radonc.2015.11.029
Fossum CC, Alabbad JY, Romak LB, et al. The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis. J Gastrointest Oncol. 2017;8(4):650–8.
doi: 10.21037/jgo.2017.06.07
Sager O, Dincoglan F, Demiral S, et al. A concise review of pelvic radiation therapy (RT) for rectal cancer with synchronous liver metastases. Int J Surg Oncol. 2019;21(2019):5239042.
Zhang C-H, Pan Y-B, Zhang Q-W, et al. The influence of local therapy on the survival of patients with metastatic rectal cancer: a population-based, propensity-matched study. J Cancer Res Clin Oncol. 2017;143(9):1891–903.
doi: 10.1007/s00432-017-2442-2
Afshari K, Chabok A, Naredi P, et al. Prognostic factors for survival in stage IV rectal cancer: a Swedish nationwide case–control study. Surg Oncol. 2019;29:102–6.
doi: 10.1016/j.suronc.2019.04.005
Teng H-W, Lin J-K, Lin T-C, et al. Planned short-course radiation (scRT) is superior to upfront concurrent chemoradiation (CCRT) in treating metastatic rectal cancer. J Gastrointest Surg. 2020;24(5):1092–100.
doi: 10.1007/s11605-019-04256-3